Withdrawal and Re-treatment with Filgotinib in Ulcerative Colitis: Post Hoc Analyses of the Phase 2b/3 SELECTION and SELECTIONLTE Studies.

"Conflict of Interest SV reports grants from AbbVie, Galapagos, J&J, Pfizer, and Takeda; consulting and/or speaker fees from AbbVie, AbolerIS Pharma, AgomAb, Alimentiv, Arena Pharmaceuticals, AstraZeneca, Avaxia Biologics, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, CVasThera, Cytoki Pharma, Dr Falk Pharma, Ferring Pharmaceuticals, Galapagos, Genentech/Roche, Gilead, GSK, Hospira, Imidomics, Janssen, J&J, Lilly, Materia Prima, MiroBio, Morphic, MrMHealth, Mundipharma, MSD, Pfizer, Prodigest, Progenity, Prometheus, Robarts Clinical Trials, Second Genome, Shire, Surrozen, Takeda, Theravance Biopharma, Tillotts Pharma, and Zealand Pharma; and participation on a Data Safety Monitoring Board for Sanofi. BGF reports grants and personal fees from AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Janssen Biotech/Centocor, J&J/Janssen, Pfizer, Receptos, and Takeda; personal fees from Ablynx, ActoGeniX, Akebia Therapeutics, Allergan, Atlantic Pharma, Avaxia Biologics, Avir Pharma, Baxter Healthcare Corporation, Biogen Idec, BiomX Israel, Boehringer Ingelheim, Boston Pharmaceuticals, Calypso Biotech, Celgene, Elan/Biogen, enGene, Exeliom Biosciences, Ferring Pharmaceuticals, Galapagos, Genentech/Roche, gIcare Pharma, Gilead, Given Imaging, Gossamer Bio, GSK, Inception IBD, Ironwood, Japan Tobacco, Kyowa Hakko Kirin, Lexicon, Lilly, Lycera Biotech, MSD, Mesoblast Pharma, Millennium, Nestlé, Novartis, Novo Nordisk, Par’Immune, Progenity, Prometheus Biosciences, Protagonist, Q32 Bio, Qu Biologics, Salix, Shire, Sienna Biologics, Sigmoid Pharma, Synergy Pharma, Teva Pharma, TiGenix, Tillotts Pharma, UCB, Vertex, VHsquared, Vivelix Pharma, Wyeth, Zealand, and Zyngenia; and is the Senior Scientific Director of Alimentiv Inc. and a Professor of Medicine at Western University, London, ON, Canada. LP-B reports speaking fees from AbbVie, Amgen, Arena Pharmaceuticals, Biogen, Celltrion, Eli Lilly, Ferring Pharmaceuticals, Galapagos, Genentech, Gilead, Janssen Pharmaceuticals, medac Pharma, MSD, Pfizer, Sandoz, Sanofi, Takeda, Tillotts Pharma, Viatris, and Vifor; grants from Celltrion, Fresenius Kabi, and Takeda; consulting fees and/or support for meeting attendance from AbbVie, Abivax, Alimentiv, Alma Bio Therapeutics, Amgen, Applied Molecular Transport, Arena Pharmaceuticals, Biogen, Boston Pharmaceuticals, Bristol Myers Squibb, Celltrion, CONNECT Biopharm, Cytoki Pharma, Diaceutics, Eli Lilly, Enthera, Ferring Pharmaceuticals, Fresenius Kabi, Galapagos, Genentech, Gilead, Gossamer Bio, GSK, H.A.C. Pharma, IAG Image Analysis, Index Pharmaceuticals, Inotrem, Janssen, medac Pharma, Mopac, Morphic, MSD, Norgine, Novartis, OM Pharma, ONO Pharma, OSE Immunotherapeutics, Pandion Therapeutics, Par’Immune, Pfizer, Prometheus, Protagonist, Roche, Sandoz, Sublimity Therapeutics, Takeda, Theravance Biopharma, Thermo Fisher Scientific, Tigenix, Tillotts Pharma, Viatris, Vifor, and YSOPIA; participation on Data Safety Monitoring Boards or advisory boards for AbbVie, Abivax, Alimentiv, Alma Bio Therapeutics, Amgen, Applied Molecular Transport, Arena, Biogen, Bristol Myers Squibb, Celltrion, CONNECT Biopharm, Cytoki Pharma, Diaceutics, Eli Lilly, Enthera, Ferring Pharmaceuticals, Fresenius Kabi, Galapagos, Genentech, Gilead, Gossamer Bio, GSK, H.A.C. Pharma, IAG Image Analysis, Index Pharmaceuticals, Inotrem, Janssen, medac Pharma, Mopac, Morphic, MSD, Norgine, Novartis, OM Pharma, ONO Pharma, OSE Immunotherapeutics, Pandion Therapeutics, Par’Immune, Pfizer, Prometheus, Protagonist, Roche, Sandoz, Takeda, Theravance Biopharma, Thermo Fisher Scientific, Tigenix, Tillotts Pharma, Viatris, Vifor, and Ysopia; and stock options from CTMA. AO, MF, and AdH are employees and shareholders of Galapagos NV. GR reports personal fees and/or speaker fees from AbbVie, AstraZeneca, Augurix Diagnostics, Bristol Myers Squibb, Boehringer Ingelheim, Calypso Biotech, Celgene, Dr Falk Pharma, Eli Lilly, Ferring Pharmaceuticals, Fisher, Genentech, Gilead, Janssen, MSD, Novartis, Pfizer, Phadia, Pierre Fabre, Roche, Takeda, Tillotts Pharma, UCB, Vifor Pharma, Vital Solutions, and Zeller; and grants from AbbVie, Ardeypharm, Augurix Diagnostics, Calypso Biotech, Dr Falk Pharma, Flamentera, MSD, Novartis, Pfizer, Roche, Takeda, Tillotts Pharma, UCB, and Zeller; support for meeting attendance from AbbVie, Amgen, and Takeda; patent(s) with PharmaBiome; and participation on Data Safety Monitoring Boards for Bristol Myers Squibb, Dr Falk Pharma, and Dr Wolff Group."

"Funding The SELECTION trial was sponsored by Gilead Sciences, Inc. The SELECTIONLTE trial was sponsored by Galapagos NV, who funded these analyses."